The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named its first two designated radiopharmaceutical therapy centers of excellence: Stanford Health Care in Stanford, CA, and the Dana-Farber Brigham Cancer Center in Boston.
The two centers stand out in both radiopharmaceutical therapy and research, SNMMI said.
SNMMI created the Radiopharmaceutical Therapy Center of Excellence program to certify sites that meet strict regulatory, training, qualification, experience, and performance criteria for radiopharmaceutical therapy. The designation assures patients, their families, referring physicians, and payers that rigorous procedures are in place and followed at these centers.
"Radiopharmaceutical therapies represent a growing sector in the field in which nuclear medicine professionals act as 'nuclear oncologists' for patients, evaluating them, providing treatment options and delivering therapy," SNMMI said.
The need for recognized, high-quality radiopharmaceutical therapy centers is expected to increase, with several radiopharmaceutical therapies recently approved and new ones pending approval by the U.S. Food and Drug Administration, SNMMI added.
